PSP Research LLC Purchases New Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

PSP Research LLC purchased a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) during the 4th quarter, Holdings Channel reports. The fund purchased 21,879 shares of the company’s stock, valued at approximately $547,000. Centessa Pharmaceuticals accounts for about 0.5% of PSP Research LLC’s portfolio, making the stock its 13th largest position.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Avoro Capital Advisors LLC grew its holdings in Centessa Pharmaceuticals by 116.2% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after acquiring an additional 5,808,080 shares during the last quarter. Federated Hermes Inc. bought a new stake in Centessa Pharmaceuticals during the 3rd quarter worth approximately $42,429,000. Adage Capital Partners GP L.L.C. grew its holdings in Centessa Pharmaceuticals by 20.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after acquiring an additional 1,449,000 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in Centessa Pharmaceuticals during the 2nd quarter worth approximately $16,052,000. Finally, Commodore Capital LP grew its holdings in Centessa Pharmaceuticals by 39.3% during the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after acquiring an additional 930,711 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Stock Up 0.2%

Centessa Pharmaceuticals stock opened at $39.70 on Wednesday. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $10.95 and a 12-month high of $40.26. The firm’s fifty day moving average is $35.81 and its 200 day moving average is $29.07. The company has a market capitalization of $5.92 billion, a PE ratio of -22.18 and a beta of 1.13.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Analyst Ratings Changes

CNTA has been the topic of a number of research reports. B. Riley Financial lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Wells Fargo & Company downgraded shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $35.00 to $42.00 in a research report on Monday, April 20th. Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Stephens downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $40.70.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the transaction, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Karen M. Anderson sold 120,029 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 309,112 shares of company stock worth $8,424,535. Corporate insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.